General Partner, Canaan Partners
Timothy Shannon, M.D., is a general partner at Canaan Partners, where he focuses on early-stage biopharmaceutical companies. He is chairman of the board of Arvinas (ARVN, IPO 2018) and IDEAYA Biosciences (IDYA, IPO 2019) and is a director at Vivace Therapeutics and RallyBio. Prior successful companies include NextCure (NXTC, IPO 2019), CytomX (CTMX, IPO 2015), Civitas Therapeutics (acquired by Acorda in 2014 for $525m) and Novira Therapeutics (acquired by Johnson & Johnson in 2015, amount undisclosed). Shannon previously was president and chief executive officer of CuraGen, a publicly traded biopharmaceutical company. CuraGen merged with Celldex Therapeutics in 2009, when Shannon served on the board. Prior to that he was senior vice president of global medical development for Bayer’s Pharmaceutical Business Group. Shannon began his career as an assistant professor of pulmonary and critical care medicine at Yale University School of Medicine, received his M.D. from the University of Connecticut, and earned his B.A. from Amherst College.